Quantifying the Impact of AI-Enabled Trial Delivery

This Deutsche Bank report quantifies the impact of AI- and ML-enabled trial delivery on clinical development. Drawing on data from the Tufts Center for the Study of Drug Development and Whitlock, Shah et al. (2026), it finds that AI/ML is capable of driving tangible cost savings in Phase III clinical trials, with full AI-enablement having the potential to reduce the resource burden of biometrics activities by up to 28%. On average, an approximately 18% time reduction has been observed when AI/ML solutions are used for clinical trials. The report also notes that the pharmaceutical industry has historically been slow to adopt new technology, as illustrated by analogous technology adoption curves.